Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
OPERATING ACTIVITIES    
Net income $ 1,412 $ 800
Adjustments to reconcile net income to net cash provided by operating activities:    
Provision for doubtful accounts (141) (122)
Depreciation 8,335 8,621
Loss on disposal of and reserve adjustments for medical equipment 678 1,278
Gain on sale of medical equipment (1,863) (1,990)
Amortization of intangible assets 743 743
Amortization of deferred debt issuance costs 58 99
Stock-based compensation 3,276 2,799
Deferred income taxes 1,383 325
Changes in assets - (increase)/decrease:    
Accounts receivable (1,348) (1,035)
Inventories (298) (1,270)
Other current assets 385 (1,090)
Other assets 1,137 (2,304)
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (1,229) (289)
NET CASH PROVIDED BY OPERATING ACTIVITIES 12,528 6,565
INVESTING ACTIVITIES    
Purchase of medical equipment (12,162) (8,503)
Purchase of property and equipment (562) (616)
Proceeds from sale of medical equipment, property and equipment 2,754 3,429
NET CASH USED IN INVESTING ACTIVITIES (9,970) (5,690)
FINANCING ACTIVITIES    
Principal payments on long-term debt (40,415) (43,160)
Cash proceeds from long-term debt 39,231 42,788
Debt issuance costs 0 (229)
Common stock repurchased as part of share repurchase program (981) (153)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (625) (1,157)
Cash proceeds from exercise of options and ESPP 381 1,032
NET CASH USED IN FINANCING ACTIVITIES (2,409) (879)
Net change in cash and cash equivalents 149 (4)
Cash and cash equivalents, beginning of period 231 165
Cash and cash equivalents, end of period $ 380 $ 161